Show simple item record

dc.contributor.authorCraven, RA
dc.contributor.authorVasudev, NS
dc.contributor.authorBanks, RE
dc.date.accessioned2018-08-06T13:15:31Z
dc.date.issued2013-04
dc.identifier6, SI
dc.identifier.citationCLINICAL BIOCHEMISTRY, 2013, 46 pp. 456 - 465
dc.identifier.issn0009-9120
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2274
dc.identifier.eissn1873-2933
dc.identifier.doi10.1016/j.clinbiochem.2012.11.029
dc.description.abstractWorldwide, over 273,000 people are diagnosed with renal cancer each year. Approximately one third of patients present with locally advanced or metastatic disease and although surgery is largely curative in those with localised disease, about one third of these patients will subsequently relapse. Renal cancer is resistant to conventional chemotherapy and radiotherapy but increased understanding of the underlying tumour biology is leading to the use and development of targeted therapies, such as tyrosine kinase inhibitors targeting pathways downstream of the von Hippel Lindau tumour suppressor gene. There are no biomarkers in routine clinical use in renal cancer but they are urgently needed for enabling earlier diagnosis, differential diagnosis of histological subtypes and their variants, risk stratification to allow personalised follow-up and prediction and monitoring of response and toxicity to targeted therapies. Several groups are now applying proteomic strategies in biomarker discovery in renal cancer. We review the progress being made in these studies and discuss the strategies needed to ensure effective translation of findings to the clinic. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
dc.format.extent456 - 465
dc.languageeng
dc.language.isoeng
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD
dc.titleProteomics and the search for biomarkers for renal cancer
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.clinbiochem.2012.11.029
rioxxterms.licenseref.startdate2013-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCLINICAL BIOCHEMISTRY
pubs.notesaffiliation: Banks, RE (Reprint Author), St James Univ Hosp, Clin & Biomed Prote Grp, Canc Res UK Ctr, Leeds Inst Mol Med, Beckett St, Leeds LS9 7TF, W Yorkshire, England. Craven, Rachel A.; Banks, Rosamonde E., St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Ctr, Leeds LS9 7TF, W Yorkshire, England. Vasudev, Naveen S., Inst Canc Res, London SW3 6JB, England. keywords: Proteomics; Renal cancer; Biomarkers; Genomics keywords-plus: LINDAU TUMOR-SUPPRESSOR; SERUM AMYLOID ALPHA; SELDI-TOF-MS; CELL CARCINOMA IDENTIFICATION; HUMAN PLASMA PROTEOMICS; HUMAN KIDNEY CANCER; MASS-SPECTROMETRY; PROTEIN EXPRESSION; QUANTITATIVE PROTEOMICS; CANDIDATE BIOMARKERS research-areas: Medical Laboratory Technology web-of-science-categories: Medical Laboratory Technology author-email: [email protected] orcid-numbers: Banks, Rosamonde/0000-0002-0042-8715 number-of-cited-references: 147 times-cited: 8 usage-count-last-180-days: 0 usage-count-since-2013: 31 journal-iso: Clin. Biochem. doc-delivery-number: 120FI unique-id: ISI:000317155800007 da: 2018-08-06
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Biology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Biology
pubs.volume46
pubs.embargo.termsNot known
icr.researchteamTumour Biologyen_US
dc.contributor.icrauthorVasudev, Naveenen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record